June 30, 2009. Corresponding medical records of included cases were then reviewed, with cases of icSCC treated via curettage alone included in this study. Patient and tumor characteristics were recorded, including duration of follow-up through the end of the study period (May 17, 2015) . Tumors were considered recurrent if there was documentation of clinician or patient suspicion for recurrence with histologic confirmation of icSCC at the same site.
Overall, 89 individual lesions from 80 unique patients met inclusion criteria and were included in this study. Duration of follow-up extended from 0 to 2502 days (6.8 years), with a median of 6 years. Most patients were male, with a mean age of 76 years at the time of diagnosis (Table I) . Forty-four percent of lesions were located in low-risk sites, with a mean pretreatment size of 0.9 cm (range, 0.3-2.5 cm). Most lesions (76%) had tumor present at histologic margins, and 91% were well-differentiated (Table  II) . Three recurrences were identified (overall cure rate, 97%), 2 of which were located on high-risk sites, and 2 of the 3 recurrent lesions initially had positive histologic margins (Table II) . One recurrent lesion was located on a high-risk site and was present at histologic margins before treatment with curettage. All recurrent lesions were welldifferentiated histologically (Table II) . Time to recurrence (days) was 60, 68, and 78; 2 recurrences were initially curetted by the same staff dermatologist.
Limitations of this study include incomplete medical records and suboptimal site documentation, potentially leading to missed recurrent tumors. Additionally, variation in curettage technique may have been present between clinicians (eg, disposable versus reusable curettes, number of passes with the curette) and practitioners may have preselected tumors and patients with certain characteristics for curettage alone.
In conclusion, this study demonstrated a 97% cure rate of icSCC by curettage alone. 4 Providers with adequate training in this technique should consider this treatment in icSCC with comparable features because it can be an efficient and effective modality for treating this tumor. Our small sample size precludes strong recommendations for precise tumor or technique selection. A prospective study is needed to further explore risk factors for recurrence as well as cosmetic outcomes, healing time, and complications associated with this procedure. Efficacy of autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study
To the Editor: It has been reported that hyaluronic acid (HA) and autologous platelet-rich plasma (PRP) play an important role in the tissue regeneration process by stimulating cell signaling at the injection site. The aim of this open label prospective study was to assess the clinical benefit of combining PRP and HA (PRP-HA) effectors, which have synergic effects on skin firmness and elasticity, using objective assessment by a Cutometer MPA 580 (CourageKhazaka Electronic GmbH, Cologne, Germany) 1 of the software-evaluated skin mechanical parameter R:R5 (net elasticity) together with a validated subjective scale, the FACE-Q. NCT02832583. The BCT-HA kit (RegenLab SA, Le Mont sur Lausanne, Switzerland), which consists of tubes designed to prepare a mix of PRP and HA, was used. The hyaluronic acid (40 mg [2% wt/vol] of noncross-linked HA, 1550 KDa) was used at the same proportion as PRP (2 mL of PRP and 2 mL of HA). 3 Mesotherapy was performed using topical anesthesia (EMLA cream 5%, Astrazeneca AB S, Sodertalje, Sweden) at 0, 1, and 2 months by injecting 4 mL of the mixture per cheek. The procedure was performed in 2 steps. The first step consisted of deep intradermal injections of PRP-HA using a 1-mL syringe with a 32-guage needle every 5 mm per cheek. The second step consisted of spreading 1 mL of the mixture per cheek followed by intradermal punctures made by using a grid with punctures every 1 mm and a 1-mm SkinRoller (Aesthetic Group, Puiseux-le-Hauberger, France) (Fig 1) . All outcomes were assessed before injection (baseline) and at 1, 3, and 6 months after the last injection session. No subjects dropped out before the 6-month assessment.
A total of 31 patients were recruited under the assumption of a 20% dropout rate, 20% size effect from treatment, bilateral 5% alpha risk, and 80% beta risk. The mean age of the 31 patients included in the study was 51.8 plus or minus 8.5 years. Comparison of FACE-Q scores showed significant improvement at 6 months compared with baseline (44.3 6 1.9 at baseline versus 52 6 3.17 at 6 months, P ¼ .03). Similarly, biophysical measurements showed significant improvement for R5 (P ¼ .036*) from baseline (Fig 2) . No serious adverse event was reported.
In a study investigating the effect of HA on facial rejuvenation, Reuther et al 4 reported that micropuncture injections of HA increased the net elasticity parameter (R5), showing improvement in skin elasticity. Moreover, a recent study showed that 3 sessions of PRP injection at 1-month intervals resulted in significant improvement of skin elasticity and skin smoothness parameters. 5 Of note, the platelet number of PRP may vary depending on the individual from which the blood is drawn. Thus, treatment with PRP might show variable efficacy depending on the source of the PRP.
The main limitations of this study were the lack of a comparison group and the difficulty of identifying the exact role of each factor (HA, PRP, and microneedling). 
